About Accelerate Diagnostics (NASDAQ:AXDX)
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100
Debt
Debt-to-Equity RatioN/A
Current Ratio17.77%
Quick Ratio16.58%
Price-To-Earnings
Trailing P/E Ratio-21.12
Forward P/E Ratio-20.42
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.18 million
Price / Sales327.00
Cash FlowN/A
Price / CashN/A
Book Value$2.14 per share
Price / Book11.45
Profitability
EPS (Most Recent Fiscal Year)($1.16)
Net Income$-64,020,000.00
Net Margins-1,520.99%
Return on Equity-54.66%
Return on Assets-51.90%
Miscellaneous
EmployeesN/A
Outstanding Shares55,790,000
Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions
What is Accelerate Diagnostics' stock symbol?
Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."
How were Accelerate Diagnostics' earnings last quarter?
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings data on Thursday, February, 15th. The medical research company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.06. The medical research company had revenue of $2.10 million for the quarter. Accelerate Diagnostics had a negative return on equity of 54.66% and a negative net margin of 1,520.99%. View Accelerate Diagnostics' Earnings History.
What price target have analysts set for AXDX?
2 brokers have issued 1 year price targets for Accelerate Diagnostics' stock. Their forecasts range from $32.00 to $34.00. On average, they anticipate Accelerate Diagnostics' stock price to reach $33.00 in the next year. View Analyst Ratings for Accelerate Diagnostics.
What are Wall Street analysts saying about Accelerate Diagnostics stock?
Here are some recent quotes from research analysts about Accelerate Diagnostics stock:
- 1. According to Zacks Investment Research, "Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. " (2/21/2018)
- 2. BTIG Research analysts commented, "Outlook Remains The Same As the company preannounced Q4 revenue and provided FY18 revenue expectations on January 10th , the company’s formal earnings call was fairly straightforward without surprises. The messaging was largely consistent with what we learned from the company’s JPM conference presentation though we now may expect an update on progress with the FDA on the LRTI test as early as the Q1 call. Overall, we remain very positive on the technology and the total opportunity but feel the company needs to consistently hit estimates through the course of the year for the Street to regain comfort with the model. We maintain our Neutral rating. Modestly tweaking our estimates for gross margin. Our revenue estimates are unchanged but we have increased our gross margin estimates to reflect better trends in Q4. Our full year FY18 revenue estimate is $25M and we assume roughly 2/3 of revenue will be recognized in the 2H. For Q1, we model a slight uptick sequentially from Q4 revenue of $2.12M to $3.2M; of note, this estimate also seems to be lower than other estimates on the Street of $4-5M. Given the timing of hospital purchasing, we prefer to have a conservative bias in the start of the year. Valuation: Shares are Neutral rated based on our DCF analysis. Risks follow." (2/18/2018)
Who are some of Accelerate Diagnostics' key competitors?
Some companies that are related to Accelerate Diagnostics include Magellan Health (MGLN), NuVasive (NUVA), Halozyme Therapeutics (HALO), Nevro (NVRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Foundation Medicine (FMI), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Teladoc (TDOC), Evotec A.G. (EVTCY), Clovis Oncology (CLVS), Ironwood Pharmaceuticals (IRWD), Abcam (ABC), CRISPR Therapeutics (CRSP), Supernus Pharmaceuticals (SUPN), Acadia Pharmaceuticals (ACAD) and Akorn (AKRX).
Who are Accelerate Diagnostics' key executives?
Accelerate Diagnostics' management team includes the folowing people:
- Mr. Lawrence Mehren, Chief Exec. Officer, Pres and Director (Age 52)
- Mr. Steve Reichling, Chief Financial Officer, Chief Accounting Officer and Sec. (Age 40)
- Mr. Kurt Reinhardt, Head of Operations
- Dr. Romney M. Humphries Ph.D., D(ABMM), M (ASCP)CM, Chief Scientific Officer
- Mr. Steven W. Metzger, Head of Discovery & New Products (Age 44)
Has Accelerate Diagnostics been receiving favorable news coverage?
Media coverage about AXDX stock has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Accelerate Diagnostics earned a media sentiment score of 0.16 on Accern's scale. They also gave news stories about the medical research company an impact score of 48.15 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Accelerate Diagnostics?
Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Accelerate Diagnostics' stock price today?
One share of AXDX stock can currently be purchased for approximately $24.50.
How big of a company is Accelerate Diagnostics?
Accelerate Diagnostics has a market capitalization of $1.37 billion and generates $4.18 million in revenue each year. The medical research company earns $-64,020,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.
How can I contact Accelerate Diagnostics?
Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]
MarketBeat Community Rating for Accelerate Diagnostics (AXDX)
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Accelerate Diagnostics (NASDAQ:AXDX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Accelerate Diagnostics in the last 12 months. Their average twelve-month price target is $33.00, suggesting that the stock has a possible upside of 34.69%. The high price target for AXDX is $34.00 and the low price target for AXDX is $32.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.50 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $33.00 | $33.00 | $33.00 | $33.00 |
| Price Target Upside: | 34.69% upside | 31.21% upside | 10.00% upside | 17.65% upside |
Accelerate Diagnostics (NASDAQ:AXDX) Consensus Price Target History
Accelerate Diagnostics (NASDAQ:AXDX) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 2/18/2018 | BTIG Research | Reiterated Rating | Hold | | Medium |  |
| 6/5/2017 | Piper Jaffray | Reiterated Rating | Overweight | $30.00 -> $32.00 | Low | |
| 8/9/2016 | JPMorgan Chase | Boost Price Target | Overweight | $17.00 -> $25.00 | N/A | |
(Data available from 4/22/2016 forward)
Accelerate Diagnostics (NASDAQ:AXDX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Accelerate Diagnostics (NASDAQ AXDX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 50.00%
Institutional Ownership Percentage: 44.86%
Accelerate Diagnostics (NASDAQ AXDX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/5/2018 | Jack W Schuler | Director | Buy | 100 | $25.00 | $2,500.00 | | |
| 3/1/2018 | Jack W Schuler | Director | Buy | 15,000 | $25.15 | $377,250.00 | | |
| 2/22/2018 | Jack W Schuler | Director | Buy | 10,000 | $25.21 | $252,100.00 | | |
| 2/20/2018 | Jack W Schuler | Director | Buy | 20,000 | $24.95 | $499,000.00 | | |
| 11/17/2017 | Jack W Schuler | Director | Buy | 5,500 | $22.00 | $121,000.00 | | |
| 11/15/2017 | Jack W Schuler | Director | Buy | 20,000 | $20.00 | $400,000.00 | | |
| 11/13/2017 | Jack W Schuler | Director | Buy | 20,000 | $18.98 | $379,600.00 | | |
| 11/10/2017 | Jack W Schuler | Director | Buy | 51,181 | $18.67 | $955,549.27 | | |
| 11/8/2017 | Jack W Schuler | Director | Buy | 50,000 | $18.46 | $923,000.00 | | |
| 11/6/2017 | Jack W Schuler | Director | Buy | 340,964 | $18.51 | $6,311,243.64 | 44,670 | |
| 10/18/2017 | Jack W Schuler | Director | Buy | 45,000 | $20.14 | $906,300.00 | | |
| 10/16/2017 | Jack W Schuler | Director | Buy | 59,922 | $20.07 | $1,202,634.54 | | |
| 10/13/2017 | Jack W Schuler | Director | Buy | 61,300 | $19.29 | $1,182,477.00 | | |
| 10/12/2017 | Jack W Schuler | Director | Buy | 276,200 | $19.74 | $5,452,188.00 | | |
| 10/11/2017 | Jack W Schuler | Director | Buy | 51,600 | $20.27 | $1,045,932.00 | | |
| 8/21/2017 | Jack W Schuler | Director | Buy | 50,000 | $21.45 | $1,072,500.00 | | |
| 8/17/2017 | Lawrence Mehren | Insider | Sell | 223,215 | $22.40 | $5,000,016.00 | 762,381 | |
| 8/15/2017 | Jack W Schuler | Director | Buy | 8,200 | $21.35 | $175,070.00 | | |
| 8/14/2017 | Jack W Schuler | Director | Buy | 23,400 | $21.35 | $499,590.00 | | |
| 8/11/2017 | Jack W Schuler | Director | Buy | 80,000 | $21.43 | $1,714,400.00 | | |
| 6/21/2017 | Steven Reichling | Insider | Sell | 30,000 | $28.90 | $867,000.00 | 30,700 | |
| 1/9/2017 | Lawrence Mehren | Insider | Sell | 400,068 | $19.00 | $7,601,292.00 | | |
| 1/9/2017 | Matthew Strobeck | Director | Buy | 8,000 | $19.00 | $152,000.00 | 2,045,560 | |
| 6/30/2016 | Jack W Schuler | Director | Buy | 90,147 | $13.95 | $1,257,550.65 | | |
| 6/14/2016 | Jack W Schuler | Director | Buy | 14,033 | $13.67 | $191,831.11 | | |
| 6/13/2016 | Jack W Schuler | Director | Buy | 15,967 | $13.70 | $218,747.90 | | |
| 6/10/2016 | Jack W Schuler | Director | Buy | 88,316 | $14.69 | $1,297,362.04 | | |
| 6/9/2016 | Jack W Schuler | Director | Buy | 101,272 | $14.14 | $1,431,986.08 | | |
| 5/20/2016 | Jack W Schuler | Director | Buy | 4,270 | $11.04 | $47,140.80 | | |
| 5/17/2016 | Jack W Schuler | Director | Buy | 10,000 | $11.45 | $114,500.00 | | |
| 5/16/2016 | Jack W Schuler | Director | Buy | 11,511 | $11.91 | $137,096.01 | | |
| 5/13/2016 | Jack W Schuler | Director | Buy | 20,000 | $12.45 | $249,000.00 | | |
| 2/9/2016 | Jack W Schuler | Director | Buy | 600,000 | $11.86 | $7,116,000.00 | | |
| 2/8/2016 | Jack W Schuler | Director | Buy | 20,000 | $12.32 | $246,400.00 | | |
| 2/5/2016 | Jack W Schuler | Director | Buy | 7,308 | $12.65 | $92,446.20 | | |
| 2/4/2016 | Jack W Schuler | Director | Buy | 10,000 | $12.98 | $129,800.00 | | |
| 2/3/2016 | Jack W Schuler | Director | Buy | 50,100 | $13.09 | $655,809.00 | | |
| 2/2/2016 | Jack W Schuler | Director | Buy | 20,000 | $13.46 | $269,200.00 | | |
| 1/21/2016 | Jack W Schuler | Director | Buy | 10,000 | $15.02 | $150,200.00 | | |
| 12/10/2015 | Larry N Feinberg | Major Shareholder | Buy | 117,647 | $17.00 | $1,999,999.00 | 173,079 | |
| 11/5/2015 | Jack W Schuler | Director | Buy | 11,899 | $16.81 | $200,022.19 | | |
| 11/4/2015 | Jack W Schuler | Director | Buy | 52,837 | $16.81 | $888,189.97 | | |
| 10/22/2015 | Jack W Schuler | Director | Buy | 2,160 | $15.82 | $34,171.20 | | |
| 9/29/2015 | Brink Frank Jm Ten | Director | Buy | 9,800 | $15.24 | $149,352.00 | 9,800 | |
| 8/26/2015 | Jack W Schuler | Director | Buy | 10,000 | $17.81 | $178,100.00 | | |
| 8/25/2015 | Jack W Schuler | Director | Buy | 10,000 | $18.56 | $185,600.00 | | |
| 4/17/2015 | Jack W Schuler | Director | Buy | 11,000 | $21.94 | $241,340.00 | | |
| 3/19/2015 | Matthew Strobeck | Director | Buy | 2,000 | $22.04 | $44,080.00 | | |
| 3/9/2015 | Jack W Schuler | Director | Buy | 22,584 | $17.18 | $387,993.12 | | |
| 1/5/2015 | Jack W Schuler | Director | Buy | 18,000 | $18.93 | $340,740.00 | | |
| 9/22/2014 | Jack W Schuler | Director | Buy | 2,588 | $16.44 | $42,546.72 | | |
| 9/19/2014 | Jack W Schuler | Director | Buy | 32,411 | $16.67 | $540,291.37 | | |
| 8/21/2014 | Jack W Schuler | Director | Buy | 2,900 | $16.79 | $48,691.00 | | |
| 8/5/2014 | Larry N Feinberg | Major Shareholder | Buy | 11,835 | $15.92 | $188,413.20 | | |
| 8/5/2014 | Matthew Strobeck | Director | Buy | 20,000 | $16.70 | $334,000.00 | | |
| 8/4/2014 | Matthew Strobeck | Director | Buy | 20,000 | $16.70 | $334,000.00 | | |
| 7/16/2014 | Larry N Feinberg | Major Shareholder | Buy | 20,000 | $21.54 | $430,800.00 | | |
| 7/1/2014 | Jack W Schuler | Director | Buy | 8,698 | $25.70 | $223,538.60 | | |
| 6/30/2014 | Jack W Schuler | Director | Buy | 10,000 | $26.09 | $260,900.00 | | |
| 6/30/2014 | Larry N Feinberg | Major Shareholder | Buy | 20,000 | $25.72 | $514,400.00 | | |
| 5/12/2014 | Larry N Feinberg | Major Shareholder | Buy | 297,618 | $16.80 | $4,999,982.40 | | |
| 2/5/2014 | Larry N Feinberg | Major Shareholder | Buy | 8,554 | $24.78 | $211,968.12 | | |
| 1/27/2014 | Larry N Feinberg | Major Shareholder | Buy | 16,307 | $13.09 | $213,458.63 | | |
| 12/31/2013 | Larry N Feinberg | Major Shareholder | Buy | 84,081 | $12.29 | $1,033,355.49 | | |
| 10/30/2013 | Larry N Feinberg | Major Shareholder | Buy | 10,000 | $12.95 | $129,500.00 | | |
| 8/30/2013 | Larry N Feinberg | Major Shareholder | Buy | 16,001 | $9.76 | $156,169.76 | | |
| 8/28/2013 | Larry N Feinberg | Major Shareholder | Buy | 158,445 | $9.80 | $1,552,761.00 | | |
| 8/16/2013 | Jack W Schuler | Director | Buy | 78,494 | $7.88 | $618,532.72 | | |
| 8/14/2013 | Jack W Schuler | Director | Buy | 413,090 | $8.04 | $3,321,243.60 | | |
| 8/14/2013 | Larry N Feinberg | Major Shareholder | Buy | 36,814 | $7.24 | $266,533.36 | | |
| 8/9/2013 | Larry N Feinberg | Major Shareholder | Buy | 35,168 | $7.30 | $256,726.40 | | |
| 6/21/2013 | Larry N Feinberg | Major Shareholder | Buy | 114,250 | $8.00 | $914,000.00 | | |
| 6/12/2013 | Larry N Feinberg | Major Shareholder | Buy | 7,175 | $8.41 | $60,341.75 | | |
| 6/7/2013 | Larry N Feinberg | Major Shareholder | Buy | 45,508 | $8.33 | $379,081.64 | | |
(Data available from 1/1/2013 forward)
Accelerate Diagnostics (NASDAQ AXDX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Accelerate Diagnostics announces sizeable release of new data at ECCMID 2018
finance.yahoo.com - April 21 at 9:11 AM |
 | Brokerages Anticipate Accelerate Diagnostics, Inc. (AXDX) Will Announce Quarterly Sales of $2.79 Million
www.americanbankingnews.com - April 21 at 4:32 AM |
| Head-To-Head Comparison: Precipio (PRPO) vs. Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - April 20 at 7:18 PM |
| Zacks: Brokerages Anticipate Accelerate Diagnostics, Inc. (AXDX) to Post -$0.31 Earnings Per Share
www.americanbankingnews.com - April 19 at 9:51 AM |
| BTIG Research Reaffirms Buy Rating for Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - April 18 at 8:34 PM |
| BidaskClub Downgrades Accelerate Diagnostics (AXDX) to Hold
www.americanbankingnews.com - April 16 at 12:03 PM |
| Accelerate Diagnostics (AXDX) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 11 at 10:42 PM |
| Accelerate Diagnostics (AXDX) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 10 at 7:51 PM |
| Brokerages Expect Accelerate Diagnostics, Inc. (AXDX) Will Post Quarterly Sales of $2.62 Million
www.americanbankingnews.com - April 4 at 4:00 AM |
| Analysts Anticipate Accelerate Diagnostics, Inc. (AXDX) to Announce -$0.31 Earnings Per Share
www.americanbankingnews.com - April 2 at 9:12 AM |
| Analysts Set $26.50 Target Price for Accelerate Diagnostics Inc (AXDX)
www.americanbankingnews.com - April 1 at 1:26 AM |
| Accelerate Diagnostics (AXDX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 28 at 11:21 AM |
| Accelerate Diagnostics (AXDX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 8:44 PM |
 | Accelerate Diagnostics, Inc. Announces Pricing of $150 Million Convertible Notes Offering - GlobeNewswire (press release)
globenewswire.com - March 23 at 4:33 PM |
 | Accelerate Diagnostics (AXDX) Prices of $150 Million Convertible Notes Offering
www.streetinsider.com - March 23 at 9:19 AM |
| Accelerate Diagnostics, Inc. Announces Pricing of $150 Million Convertible Notes Offering
finance.yahoo.com - March 23 at 9:19 AM |
| Accelerate Diagnostics Inc. Announces $150 Million Convertible ... - GlobeNewswire (press release)
globenewswire.com - March 22 at 4:32 PM |
| Accelerate Diagnostics Inc. Announces $150 Million Convertible Notes Offering
finance.yahoo.com - March 22 at 9:34 AM |
| Brokerages Expect Accelerate Diagnostics Inc (AXDX) to Post ($0.31) EPS
www.americanbankingnews.com - March 13 at 5:30 PM |
| Head to Head Analysis: Luna Innovations (LUNA) and Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - March 9 at 9:09 AM |
| Accelerate Diagnostics Inc (AXDX) Director Purchases $377,250.00 in Stock
www.americanbankingnews.com - March 5 at 7:00 PM |
| Lombard Odier Asset Management USA Corp Has $3.41 Million Holdings in Accelerate Diagnostics Inc (AXDX)
www.americanbankingnews.com - March 3 at 4:42 PM |
| Next Century Growth Investors LLC Raises Holdings in Accelerate Diagnostics Inc (AXDX)
www.americanbankingnews.com - March 2 at 5:58 PM |
| Accelerate Diagnostics Inc (AXDX) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - March 1 at 9:04 AM |
| Baird Financial Group Inc. Purchases New Position in Accelerate Diagnostics Inc (AXDX)
www.americanbankingnews.com - March 1 at 4:50 AM |
| Accelerate Diagnostics Inc (AXDX) Director Purchases $252,100.00 in Stock
www.americanbankingnews.com - February 26 at 3:28 PM |
| Accelerate Diagnostics (AXDX) Upgraded at BidaskClub
www.americanbankingnews.com - February 25 at 6:03 PM |
| Jack W. Schuler Purchases 20,000 Shares of Accelerate Diagnostics Inc (AXDX) Stock
www.americanbankingnews.com - February 22 at 6:32 PM |
| Accelerate Diagnostics (AXDX) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 21 at 6:04 PM |
| BTIG Research Reaffirms "Hold" Rating for Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - February 18 at 3:09 PM |
 | Notable Friday Option Activity: AXDX, NSM, ELF
www.nasdaq.com - February 16 at 4:41 PM |
| Accelerate Diagnostics (AXDX) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 16 at 10:56 AM |
 | Accelerate Diagnostics reports 4Q loss
www.cnbc.com - February 16 at 9:03 AM |
| Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017
finance.yahoo.com - February 15 at 4:40 PM |
| Stock Traders Purchase High Volume of Call Options on Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - February 14 at 9:10 PM |
| Accelerate Diagnostics Sees Unusually Large Options Volume (AXDX)
www.americanbankingnews.com - February 11 at 1:52 AM |
| -$0.33 Earnings Per Share Expected for Accelerate Diagnostics Inc (AXDX) This Quarter
www.americanbankingnews.com - February 10 at 3:12 PM |
| Accelerate Diagnostics (AXDX) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - February 9 at 11:46 PM |
| Accelerate Diagnostics to Host Q4 and Full-Year 2017 Earnings Call on February 15, 2018
finance.yahoo.com - February 9 at 9:17 AM |
| Critical Contrast: Sirona Dental Systems (SIRO) and Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - February 8 at 1:18 AM |
| Accelerate Diagnostics Inc (AXDX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 7 at 11:56 AM |
| Notable Friday Option Activity: AXDX, MSTR, LAYN
www.nasdaq.com - January 27 at 9:38 AM |
| Accelerate Diagnostics Inc (AXDX) Expected to Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - January 24 at 3:26 PM |
| Reviewing Accelerate Diagnostics (AXDX) & Volcano (VOLC)
www.americanbankingnews.com - January 21 at 5:26 AM |
| Accelerate Diagnostics (AXDX) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 7:28 PM |
| Accelerate Diagnostics Inc (AXDX) Expected to Post FY2017 Earnings of ($1.22) Per Share
www.americanbankingnews.com - January 15 at 3:02 AM |
| Accelerate Diagnostics (AXDX) & BIOLASE (BIOL) Financial Survey
www.americanbankingnews.com - January 13 at 3:32 AM |
| Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in ... - GlobeNewswire (press release)
globenewswire.com - January 11 at 3:30 PM |
| Accelerate Diagnostics (AXDX) Reports Prelim. Q4 Revenue of $2.1M; Achieves CE-IVD Milestone for Severe Bacterial Pneumonia Assay
www.streetinsider.com - January 11 at 9:24 AM |
| Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q4
finance.yahoo.com - January 10 at 10:50 AM |
Accelerate Diagnostics (NASDAQ:AXDX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Accelerate Diagnostics (NASDAQ:AXDX) Income Statement, Balance Sheet and Cash Flow Statement
Accelerate Diagnostics (NASDAQ AXDX) Stock Chart for Sunday, April, 22, 2018
Loading chart…
